International Definition of IMCD-TAFRO: Future Perspectives

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2022 Apr 27

PMID 35474036

Authors

Yoshito Nishimura

Midori Filiz Nishimura

Yasuharu Sato

Affiliations

Soon will be listed here.

Abstract

Since thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome was first proposed in 2010, there has been considerable progress in this area, particularly regarding its association with idiopathic multicentric Castleman disease (iMCD). TAFRO syndrome is a heterogeneous category with a constellation of symptoms that can develop in the setting of infection, rheumatologic disorder, malignancy, and iMCD. Now, iMCD with TAFRO symptoms is subtyped as iMCD-TAFRO. However, confusion between TAFRO syndrome and iMCD-TAFRO remains. In this article, we discuss the current understanding and future research agenda of TAFRO syndrome and iMCD-TAFRO from the perspective of its new validated international definition.

Citing Articles

Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns.

Otsuka M, Koga T, Sumiyoshi R, Fukui S, Kaneko Y, Shimizu T Am J Hematol. 2025; 100(4):592-605.

PMID: 39865257 PMC: 11886485. DOI: 10.1002/ajh.27612.

Computed tomography findings of idiopathic multicentric Castleman disease subtypes.

Iguchi T, Nishikori A, Sato Y, Nishimura M, Iwaki N, Kojima K J Clin Exp Hematop. 2024; 64(4):292-296.

PMID: 39721711 PMC: 11786149. DOI: 10.3960/jslrt.24053.

Transcriptome analysis of the cytokine storm-related genes among the subtypes of idiopathic multicentric Castleman disease.

Nishikori A, Nishimura M, Tomida S, Chijimatsu R, Ueta H, Lai Y J Clin Exp Hematop. 2024; 64(4):297-306.

PMID: 39462545 PMC: 11786152. DOI: 10.3960/jslrt.24061.

Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.

Srkalovic G, Nijim S, Srkalovic M, Fajgenbaum D Biomedicines. 2024; 12(6).

PMID: 38927535 PMC: 11201201. DOI: 10.3390/biomedicines12061328.

TAFRO Syndrome and COVID-19.

Tane M, Kosako H, Sonoki T, Hosoi H Biomedicines. 2024; 12(6).

PMID: 38927495 PMC: 11200813. DOI: 10.3390/biomedicines12061287.

References

Kawashima M, Usui T, Okada H, Mori I, Yamauchi M, Ikeda T . TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol. 2015; 27(6):1093-1097. DOI: 10.3109/14397595.2015.1059982. View

Simons M, Apor E, Butera J, Treaba D . TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature. Case Rep Hematol. 2016; 2016:4703608. PMC: 5061930. DOI: 10.1155/2016/4703608. View

Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M . Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol. 2016; 103(6):718-23. DOI: 10.1007/s12185-016-1978-2. View

Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y . Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report. J Clin Exp Hematop. 2013; 53(1):95-9. DOI: 10.3960/jslrt.53.95. View

Fajgenbaum D, Uldrick T, Bagg A, Frank D, Wu D, Srkalovic G . International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017; 129(12):1646-1657. PMC: 5364342. DOI: 10.1182/blood-2016-10-746933. View

Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y . 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2019; 111(1):155-158. DOI: 10.1007/s12185-019-02780-1. View

Fajgenbaum D, Wu D, Goodman A, Wong R, Chadburn A, Nasta S . Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020; 95(12):1553-1561. PMC: 9547644. DOI: 10.1002/ajh.25992. View

Allegra A, Rotondo F, Russo S, Calabro L, Maisano V, Bacci F . Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: A rare case report and review of the literature. Blood Cells Mol Dis. 2015; 55(3):206-7. DOI: 10.1016/j.bcmd.2015.06.013. View

Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M . Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013; 53(1):87-93. DOI: 10.3960/jslrt.53.87. View

10.

Fujimoto S, Kawabata H, Kurose N, Kawanami-Iwao H, Sakai T, Kawanami T . Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report. Medicine (Baltimore). 2018; 96(50):e9220. PMC: 5815761. DOI: 10.1097/MD.0000000000009220. View

11.

Aoki T, Wada M, Kawashima A, Hirakawa K, Nagata A, Kagawa K . Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure. Intern Med. 2017; 56(23):3249-3254. PMC: 5742402. DOI: 10.2169/internalmedicine.8360-16. View

12.

Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S . Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a.... J Clin Exp Hematop. 2013; 53(1):57-61. DOI: 10.3960/jslrt.53.57. View

13.

Morel G, Mootien J, Guiot P, Kuteifan K . Anasarca, Fever, Thrombocytopenia, Organomegaly, and Multiorgan Failure in a 24-Year-Old Pregnant Woman. Case Rep Crit Care. 2017; 2017:3871593. PMC: 5498970. DOI: 10.1155/2017/3871593. View

14.

Wang H, Pittaluga S, Jaffe E . Multicentric Castleman disease: Where are we now?. Semin Diagn Pathol. 2016; 33(5):294-306. PMC: 5003700. DOI: 10.1053/j.semdp.2016.05.006. View

15.

Hawkins J, Pillai V . TAFRO syndrome or Castleman-Kojima syndrome: a variant of multicentric Castleman disease. Blood. 2017; 126(18):2163. DOI: 10.1182/blood-2015-07-662122. View

16.

Akiyama M, Kaneko Y, Takeuchi T . Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review. Ann Hematol. 2020; 99(11):2463-2475. DOI: 10.1007/s00277-020-04275-0. View

17.

Hiramatsu S, Ohmura K, Tsuji H, Kawabata H, Kitano T, Sogabe A . Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi. 2016; 39(1):64-71. DOI: 10.2177/jsci.39.64. View

18.

Nishimura Y, Fajgenbaum D, Pierson S, Iwaki N, Nishikori A, Kawano M . Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96(10):1241-1252. PMC: 9642098. DOI: 10.1002/ajh.26292. View

19.

Tokunaga M, Yamada M, Yoshikawa S, Kondo A, Mishima M, Inoue S . [Systemic lupus erythematosus with marked eosinophilia and clinical features mimicking TAFRO syndrome]. Rinsho Ketsueki. 2018; 59(6):688-694. DOI: 10.11406/rinketsu.59.688. View

20.

Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y . Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016; 103(6):686-92. DOI: 10.1007/s12185-016-1979-1. View